The myeloMATCH precision medicine trials (NCT05564390), funded by the NCI, were officially launched on May 16, 2024.

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Researchers identified a six-gene pattern predicting venetoclax response in multiple myeloma. This genetic insight allows for ...

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with ...

Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...